Bisoprolol

Generic Name: Bisoprolol

Brand Names: Ziac

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₃₁NO_₄

CAS Number: 66722-44-9

Unique Ingredient Identifier: Y41JS2NL6U

Background: Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure. It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-adrenergic receptor selectivity and is a useful alternative to non-selective β-blocker drugs in the treatment of hypertension such as Carvedilol and Labetalol. It may be used alone or in combination with other drugs to manage hypertension and can be useful in patients with chronic obstructive pulmonary disease (COPD) due to its receptor selectivity.

Indication: Bisoprolol is indicated for the treatment of mild to moderate hypertension. It may be used off-label to treat heart failure, atrial fibrillation, and angina pectoris.

Associated Conditions: Atrial Fibrillation, Cardiovascular Events, Chronic Stable Angina Pectoris, Heart Failure, Hypertension, Mild Hypertension, Premature Ventricular Contraction (PVC), Supraventricular Arrhythmias, Moderate Hypertension, Perioperative arrhythmia

Clinical Trials

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

Early Phase 1

Recruiting

Conditions: Leukemia
Hematopoetic Stem Cell Transplantation
Donor Lymphocyte Infusion
CAR T-Cell Therapy
Lymphoma
Cell Therapy

Interventions: Behavioral: Exercise
Drug: Placebo
Drug: Isoproterenol
Drug: Bisoprolol Fumarate Tablet 10 mg
Drug: Nadolol (1 x 80 mg) Tablets (Invamed, Inc)
Drug: Carvedilol 50 mg
Drug: Roflumilast 500 Mcg Oral Tablet

First Posted Date: 2024-10-16

Last Posted Date: 2024-10-16

Lead Sponsor: University of Arizona

Target Recruit Count: 100

Registration Number: NCT06643221

Locations: 🇺🇸
The University of Arizona, Tucson, Arizona, United States

STunning in Acute Myocardial Infarction - BAS

Phase 4

Recruiting

Conditions: Myocardial Infarct

Interventions: Drug: Dapagliflozin Oral Product
Drug: Ramipril Oral Product
Drug: Bisoprolol Oral Tablet

First Posted Date: 2024-08-20

Last Posted Date: 2025-04-04

Lead Sponsor: Vastra Gotaland Region

Target Recruit Count: 120

Registration Number: NCT06562582

Locations: 🇸🇪
Sahlgrenska University Hospital, Gothenburg, Sweden

Oral Bisoprolol Vs IV Diltiazem in Atrial Fibrillation or Flutter with Rapid Ventricular Rate.

Phase 3

Not yet recruiting

Conditions: Atrial Fibrillation with Rapid Ventricular Response
Atrial Flutter with Rapid Ventricular Response

Interventions: Drug: Oral Bisoprolol
Drug: Intravenous Diltiazem

First Posted Date: 2024-02-23

Last Posted Date: 2025-03-14

Lead Sponsor: Oman Medical Speciality Board

Target Recruit Count: 60

Registration Number: NCT06276127

Locations: 🇴🇲
Sultan Qaboos University Hospital, Muscat, Al-khod, Oman

Determination of Drug Levels for Pharmacotherapy of Heart Failure

Phase 4

Not yet recruiting

Conditions: Cardiovascular Diseases
Heart Failure With Reduced Ejection Fraction

Interventions: Drug: Nebivolol
Drug: Valsartan and Sacubitril
Drug: Carvedilol
Drug: Bisoprolol
Drug: Metoprolol
Drug: Spironolactone

First Posted Date: 2023-09-13

Last Posted Date: 2024-01-18

Lead Sponsor: University Hospital Ostrava

Target Recruit Count: 100

Registration Number: NCT06035978

Locations: 🇨🇿
University Hospital Ostrava, Ostrava, Czech Republic, Czechia

Once Versus Twice Bisoprolol Dosage Regimen in Prevention of Atrial Fibrillation Post Coronary Artery Bypass Graft Surgery

Phase 4

Recruiting

Conditions: Coronary Artery Bypass Grafting
Postoperative Atrial Fibrillation
Coronary Artery Disease

Interventions: Drug: Bisoprolol

First Posted Date: 2023-02-15

Last Posted Date: 2023-07-28

Lead Sponsor: Cairo University

Target Recruit Count: 122

Registration Number: NCT05730413

Locations: 🇪🇬
El-Demerdash Cardiac Academy Hospital, Cairo, Egypt

Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy

Phase 4

Recruiting

Conditions: Non-obstructive Hypertrophic Cardiomyopathy

Interventions: Drug: Verapamil
Drug: Bisoprolol
Drug: Placebo

First Posted Date: 2022-10-06

Last Posted Date: 2025-03-20

Lead Sponsor: Morten Steen Kvistholm Jensen

Target Recruit Count: 100

Registration Number: NCT05569382

Locations: 🇩🇰
Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark
🇩🇰
Department of Cardiology, Odense University Hospital, Odense, Denmark
🇩🇰
Department of Cardiology, Zealand University Hospital, Roskilde, Denmark

and more 1 locations

Left Atrium Reservoir Function Modulation in Patients With Atrial Fibrillation: Digoxin Versus Beta Blocker

Phase 3

Recruiting

Conditions: Atrial Fibrillation
Left Atrial Rhythm

Interventions: Drug: Digoxin 0.25 mg
Drug: Bisoprolol

First Posted Date: 2022-09-14

Last Posted Date: 2022-09-16

Lead Sponsor: University of Monastir

Target Recruit Count: 30

Registration Number: NCT05540600

Locations: 🇹🇳
Fattouma Bourguiba University hospital, Monastir, Tunisia

Pharmacogenetic Study of Bisoprolol in Egyptian Patients With Acute Coronary Syndrome

Phase 2

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Bisoprolol Fumarate

First Posted Date: 2022-09-10

Last Posted Date: 2023-06-07

Lead Sponsor: Damanhour University

Target Recruit Count: 127

Registration Number: NCT05536271

Locations: 🇪🇬
Damanhour University, Damanhūr, Behira, Egypt

Potential Drug Interactions With Bisoprolol in Egyptian Patients With ACS

Phase 2

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Bisoprolol Fumarate Tablets

First Posted Date: 2022-09-10

Last Posted Date: 2023-06-07

Lead Sponsor: Damanhour University

Target Recruit Count: 128

Registration Number: NCT05536284

Locations: 🇪🇬
Damanhour University, Damanhūr, Beheira, Egypt

Randomized Trial to Examine a Differential Therapeutic Response in Symptomatic Patients With Non-obstructive Coronary Artery Disease

Phase 4

Conditions: Microvascular Angina
Vasospastic Angina
Vasospasm, Coronary
Coronary Microvascular Dysfunction
Coronary Artery Disease
Prinzmetal Angina

Interventions: Drug: Bisoprolol
Drug: Diltiazem
Drug: Placebo

First Posted Date: 2022-03-24

Last Posted Date: 2022-03-24

Lead Sponsor: Charite University, Berlin, Germany

Target Recruit Count: 132

Registration Number: NCT05294887

Locations: 🇨🇭
Universitäres Herzzentrum Zürich, Universitätsspital Zürich, Zürich, Switzerland
🇩🇪
Kerckhoff-Klinik gGmbH, Bad Nauheim, Germany
🇩🇪
Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany

and more 12 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy